{
  "hypothesis": "h47",
  "title": "Zero-Shot Disease Prediction via Drug Properties",
  "status": "invalidated",
  "date": "2026-01-29",
  "summary": "Limited impact ceiling makes zero-shot low ROI",
  "multi_seed_analysis": {
    "seeds": [
      42,
      123,
      456,
      789,
      1024
    ],
    "avg_zero_coverage_disease_pct": 0.416,
    "avg_zero_coverage_gt_pct": 0.148,
    "avg_knn_recall": 0.37,
    "impact_10pct_zeroshot": 0.015
  },
  "key_findings": [
    "~42% of test diseases have 0% kNN coverage (consistent across seeds)",
    "BUT these diseases only contain ~15% of GT pairs (avg 1.6 drugs/disease)",
    "Non-zero diseases: avg 9.9 drugs/disease (6x more GT pairs)",
    "Impact ceiling: 10% zero-shot recall adds only +1.5 pp to overall R@30"
  ],
  "category_breakdown": {
    "k_nearest_selection_failures": {
      "count": 29,
      "description": "GT drugs exist in training but k=20 fails to find right neighbors"
    },
    "truly_novel_drugs": {
      "count": 10,
      "unique_drugs": 9,
      "description": "GT drugs not in any training disease GT"
    }
  },
  "recommendation": "Deprioritize zero-shot approaches; focus on improving kNN for the 85% of GT pairs with coverage"
}